Business Context and Reporting Period
This Form 8-K, filed on November 26, 2025, by Moleculin Biotech, Inc. (NASDAQ: MBRX), reports the implementation of a 1-for-25 reverse stock split. The split was approved by stockholders at the annual meeting on August 18, 2025, and became effective at 12:01 a.m. Eastern Time on December 1, 2025. The company is incorporated in Delaware and headquartered in Houston, Texas.
Key Financial Metrics
The filing provides retrospective financial data adjusted for the reverse stock split. The company reported net losses for all periods presented; revenue, profit margins, cash flow, debt, and liquidity metrics are not disclosed in this specific filing.
| Period | Net Loss (Pre-Split) | Net Loss Per Share (Pre-Split) | Net Loss Per Share (Post-Split) | Weighted Avg Shares (Post-Split) |
|---|---|---|---|---|
| Year Ended Dec 31, 2024 | $(26,048) thousand | $(7.57) | $(189.14) | 137,720 |
| Year Ended Dec 31, 2023 | $(28,215) thousand | $(14.28) | $(357.04) | 79,024 |
| Three Months Ended Sep 30, 2025 | $(25,399) thousand | $(0.68) | $(17.02) | 1,492,178 |
| Nine Months Ended Sep 30, 2025 | $(49,112) thousand | $(2.36) | $(58.95) | 833,092 |
Note: Net loss figures for 2023 and 2024 were retrospectively adjusted due to a change in accounting policy in September 2025.
Material Changes
- Share Count Reduction: Outstanding common shares will be reduced from approximately 51.6 million to approximately 2.07 million.
- Capital Structure: Authorized shares remain at 500 million. Par value remains $0.001 per share.
- Trading Details: Post-split trading begins December 1, 2025, under ticker "MBRX" with a new CUSIP number (60855D408).
- Accounting Policy Change: Historical net losses for 2023 and 2024 were adjusted upward (more negative) due to a policy change effective September 30, 2025.
Guidance, Outlook, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures related to the stock split. Unusual items include specific adjustments to outstanding warrants:
- Series E Warrants: If the volume-weighted average price (VWAP) during the specified period is below the exercise price, the exercise price will be reduced to that VWAP. The number of shares issuable will be adjusted to keep the aggregate price unchanged, subject to a $3.00 per share floor.
- Series F Warrants: Similar price reduction provisions apply if the VWAP is below the exercise price.
- Fractional Shares: No fractional shares will be issued; holders will receive cash in lieu of fractions based on the average closing price of the five trading days preceding the split.
Investor Verification Checklist
- Verify the new CUSIP number (60855D408) for post-split trading on December 1, 2025.
- Confirm the treatment of fractional shares and the specific cash payout calculation method.
- Review the impact of the accounting policy change on historical financial statements for 2023 and 2024.
- Check the specific exercise price adjustments for Series E and Series F warrants based on the VWAP calculation.
- Confirm the reduction in outstanding shares from 51.6 million to 2.07 million.